根據交易所公(gong)(gong)告,珠海潤都制藥股(gu)份(fen)有限公(gong)(gong)司于(yu)2017年12月26日進(jin)行(xing)(xing)(xing)(xing)網上和(he)網下申購。本(ben)次發(fa)行(xing)(xing)(xing)(xing)股(gu)份(fen)數(shu)(shu)量(liang)(liang)為(wei)　2,500　萬(wan)股(gu),全部為(wei)公(gong)(gong)開(kai)發(fa)行(xing)(xing)(xing)(xing)新(xin)股(gu),公(gong)(gong)司股(gu)東不進(jin)行(xing)(xing)(xing)(xing)公(gong)(gong)開(kai)發(fa)售股(gu)份(fen),本(ben)次發(fa)行(xing)(xing)(xing)(xing)后公(gong)(gong)司總股(gu)本(ben)不超(chao)過　10,000　萬(wan)股(gu)。回撥(bo)機(ji)制啟動前(qian),本(ben)次發(fa)行(xing)(xing)(xing)(xing)網下初(chu)始(shi)發(fa)行(xing)(xing)(xing)(xing)數(shu)(shu)量(liang)(liang)為(wei)　1,500　萬(wan)股(gu),占本(ben)次發(fa)行(xing)(xing)(xing)(xing)總量(liang)(liang)的　60.00%;網上初(chu)始(shi)發(fa)行(xing)(xing)(xing)(xing)數(shu)(shu)量(liang)(liang)為(wei)　1,000　萬(wan)股(gu),占本(ben)次發(fa)行(xing)(xing)(xing)(xing)總量(liang)(liang)的　40.00%。

　　【公司簡介】

　　公(gong)(gong)司是一家(jia)藥物研發、生產、營銷(xiao)為一體的現代(dai)化(hua)高(gao)科(ke)(ke)技(ji)(ji)(ji)企(qi)(qi)業(ye)(ye)。公(gong)(gong)司主營化(hua)學藥制劑、化(hua)學原料藥、醫(yi)藥中間體。產品(pin)涵(han)蓋(gai)心腦血(xue)管、消化(hua)、麻(ma)醉等各個領域,擁有50多個生產批件和(he)10多項新藥證書,公(gong)(gong)司是國家(jia)高(gao)新技(ji)(ji)(ji)術企(qi)(qi)業(ye)(ye)、國家(jia)火炬計(ji)劃(hua)重(zhong)點高(gao)新技(ji)(ji)(ji)術企(qi)(qi)業(ye)(ye)、廣(guang)東(dong)省(sheng)創新型(xing)企(qi)(qi)業(ye)(ye)、廣(guang)東(dong)省(sheng)民營科(ke)(ke)技(ji)(ji)(ji)企(qi)(qi)業(ye)(ye)、廣(guang)東(dong)省(sheng)醫(yi)藥行(xing)業(ye)(ye)重(zhong)大貢獻(xian)企(qi)(qi)業(ye)(ye)。公(gong)(gong)司的技(ji)(ji)(ji)術中心被(bei)認定為廣(guang)東(dong)省(sheng)企(qi)(qi)業(ye)(ye)技(ji)(ji)(ji)術中心,具有較強的技(ji)(ji)(ji)術創新能力和(he)堅(jian)實的科(ke)(ke)研基礎。